46 results about "Peptide formation" patented technology

The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.

The following application relates to nanotemplates, nanostructures, nanoarrays and nanodevices formed from wild-type and mutated chaperonin polypeptides, methods of producing such compositions, methods of using such compositions and particular chaperonin polypeptides that can be utilized in producing such compositions.

A self-assembling peptide constituted by D-amino acid is named as d-RAD16 and has an amino acid sequence represented by SEQ ID NO.1 in a sequence list. Test shows that hydrogel formed by the self-assembling peptide can be used for preparing a moisture keeping and water locking agent, and has the function of stopping bleeding rapidly for wound, so that the hydrogel can be used for preparing a hemostatic drug suiting clinical application by adding a pharmaceutically acceptable carrier or excipient. Nanofiber scaffold formed by the self-assembling peptide supports the growth of various cells and can be used as the substrate material for 3D cell culture. The substrate material for 3D cell culture can simulate the in-vivo environment to support the 3D growth of cells in the substrate, thereby providing a cell 3D culture drug screening mode capable of simulating the in-vivo environment and improving the success rate for the development of new drugs.

The present invention relates to skin care compositions providing a method of enhancing the remodeling of age damaged and sun damaged skin in mammals utilizing an elastin peptide (EP) ligand of the general formula (GXXPG)n and in particular the sequences of (VGVAPG)n and / or (GVAPGV)n, and / or (VAPGVG)n and / or (APGVGV)n and / or (PGVGVA)n and / or (GVGVAP)n and a galactosugar which modulates the effect of the elastin peptide ligand(EP) on its lectin the Elastin-Binding Receptor (EBR). wherin A is a peptide-forming residue of L-alanine; G is a peptide-forming residue of glycine P is a peptide-forming residue of L-proline V is a peptide-forming residue of L-valine X is a peptide-forming residue of a single unspecified amino acid Peptide representations in this application conform to the standard practice of writing the NH2-terminal amino acid residue at the left of the formula and the CO2 H-terminal amino acid residue at the right.

In accordance with the present invention, it has been discovered that compounds which modulate the γ-secretase enzyme to make more of the shorter, less toxic and less aggregation-prone Aβ peptides (such as Aβ37 and Aβ38), while making less of the longer and more toxic and aggregation-prone AB peptides (such as AB40 and AB42) are useful as gamma-secretase modulators. In addition, these GSM compounds have further been discovered to have the selective property of modulating the formation of various AB peptides, while not inhibiting the overall activity of the γ-secretase enzyme. Thus, such compounds do not impede other critical functions of the γ-secretase enzyme, such as generating fragments from Notch that appear to control gene expression and cell differentiation. Therefore, in accordance with the present invention, there are provided screening assays useful for determining whether test compounds have GSM activity; accordingly, invention assays facilitate the identification of new gamma-secretase modulators. Such screening assays can be performed in a variety of ways, e.g., by assessing whether test compounds: lower the level of Aβ42 peptide, increase the level of Aβ37 and / or Aβ38 peptides, have substantially no effect on the processing of other γ-secretase substrates, and / or interact with at least one component of the γ-secretase complex. Also provided in accordance with the present invention are compounds having gamma-secretase modulatory activity as identified by any of the methods described herein; methods for producing formulations useful for modulating gamma-secretase activity, as well as the resulting formulations; methods for modulating gamma-secretase activity employing compounds identified according to invention methods and / or invention formulations, and the like.

The invention relates to a preparation method of a specific functional magnetic fluid; the preparation method is characterized in that water solution containing Fe<+3> and Fe<+2> is taken as raw material, the hydrolysis and the surface modification with NaOH water solution and poly-5-hydroxymethyl-furfural water solution in a supergravity field are carried out to obtain the surface modified magnetic fluid, the surface modified magnetic fluid is further coupled and combined with a synthesis oriented peptide to obtain the specific functional magnetic fluid with biocompatibility, biodegradability, bio-penetrating, magnetic response, nanoparticle property and the like; poly-5-hydroxymethyl-furfural is a soluble polymer organic matter which is obtained by polymerization of a biobased material 5-hydroxymethyl-furfural, the synthesis oriented peptide is generated by peptide formation reaction of various amino acids in an organic solvent under the action of a catalyst and at a certain temperature, and the oriented peptides with the different specific functions and the different uses can be obtained by controlling the types of the amino acids, the mixture ratio, the synthesis process conditions, etc.

The invention relates to novel chlorin e6 derivatives, pharmaceutically acceptable salts thereof, as well as preparation methods and applications of the novel chlorin e6 derivatives and the pharmaceutically acceptable salts and belongs to the technical field of medicines. The chlorin e6 ether amino acid derivatives comprise compounds shown as the general structural formula I and optical isomers ofthe general structural formula I. The preparation method of the novel chlorin e6 derivatives comprises steps as follows: 3-vinyl in chlorin e6 is etherified, and 15-ethylcarboxyl and amino acid are subjected to peptides formation. The chlorin e6 ether amino acid derivatives and the pharmaceutically acceptable salts thereof can be taken as photodynamic antitumor drugs for application. Compared with an existing clinically applied similar photosensitizer talaporfin, the chlorin e6 ether amino acid derivatives have the advantages of being high in photodynamic antitumor activity, high in ratio ofdark toxicity to phototoxicity and the like and can be applied to preparation of new photodynamic antitumor drugs including photodynamic cancer treating drugs, photodynamic treatment drugs for benignvascular diseases such as senile macular degeneration and nevus flammeus as well as photodynamic treatment drugs for condyloma acuminate.

A composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.

The present invention examines the interaction between an angiopoietin-1 mimetic peptide, QHREDGS (glutamine-histidine-arginine-glutamic acid-aspartic acid-glycine-serine (SEQ ID NO: 1)) immobilized to a collagen-chitosan hydrogel, and murine bone marrow derived macrophages. When macrophages were cultured in the presence of the peptide conjugated to a hydrogel, both pro-inflammatory and anti-inflammatory cytokines were produced, in contrast to the application of soluble peptide which elicited minimal cytokine secretion. This indicates a unique macrophage polarization with covalently immobilized peptide hydrogels, which can be beneficial in the context of the wound microenvironment.

The invention discloses a compound of PSCA (Prostate Stem Cell Antigen) polypeptide and nucleic acid, which is a granular compound obtained by the way that through positive and negative charge attraction, a PSCA gene recombination eukaryotic expression vector is packaged by fusogenic peptide formed by a positive ion peptide DNA (Deoxyribonucleic Acid) transport carrier and HLA-A2 limit CTL (Cytotoxic T Lymphocyte) epitope peptide PSCA 14-22. The preparation method comprises the steps that in buffer salt solution with pH of 7.2-7.6, the fusogenic peptide and the PSCA gene recombination eukaryotic expression vector are added according to a certain positive and negative charge ratio, are then mixed, and are left standing under room temperature for 0.5-1.5 hours to obtain the compound; the compound is not only combined with the advantages of DNA vaccine and epitope peptide vaccine, but also can imitate natural virus to directly 'infect' APC (Antigen Presenting Cell) and other immune cells, so as to stimulate strong CTL response in vivo. The compound is expected to break down selftolerance of tumour antigen, can be used to prepare prostate cancer therapeutic vaccine of more than 50 % of population in China, and has potential and good development and application prospect in the prostate cancer immunization therapy field.

The invention discloses a gel candy rich in small-molecule protein peptide and a preparation method of the gel candy. The candy comprises the components of small-molecule protein peptide, grease, gelatin, arabic gum, white granulated sugar, glucose syrup, an acid agent, an essence and a pigment, and is obtained by dissolving and uniformly emulsifying the components, performing pouring shaping, demolding and drying. The gel candy disclosed by the invention can be used for overcoming the defects that the existing gel candy is very strong in candy body toughness and is difficult to chew; the grease and the arabic gum are added into the gel candy rich in small-molecule protein peptide, and the grease is implanted into a gel netlike structure formed by glutin and small-molecule protein peptide to ensure that the gel netlike structure is changed, the toughness of the gel netlike structure is greatly reduced, but the gel property is basically not changed, so that the sugar body of the gel candy becomes soft and easy to chew; and the preparation method disclosed by the invention is simple and convenient, is high in production efficiency, and has very good application effect and popularization significance.

The present invention provides a self-assembled polypeptide, a preparation method and an application thereof, wherein the sequence of the polypeptide is an amino acid sequence represented by SEQ ID NO:1, the self-assembled polypeptide is synthesized through a chemical synthesis method, and the application is an application of the self-assembled polypeptide in drug self-assembly or pharmaceutical composition preparation. According to the present invention, the water solubility of the drug can be increased with the complex formed from the self-assembled polypeptide; and the drug intake can be easily reduced with the pharmaceutical composition prepared from the complex formed by adopting the self-assembled polypeptide so as to reduce the medical cost.

The invention discloses a small molecule peptide as well as a preparation method and application of the small molecule peptide as a nano drug carrier. The structural formula of the peptide is Ac-LVVLKKK (pY)-NH2, and the peptide can be self-assembled in a Hepes solution to form spherical nanoparticles. Spherical nanoparticles formed by the peptide can be used as a drug carrier for entrapping insoluble antitumor drugs, so that the toxic and side effects of the insoluble antitumor drugs are reduced, and the bioavailability of the insoluble antitumor drugs is improved. The small molecule polypeptide designed by the invention has enzyme responsiveness and self-assembly morphology transformation capability, can respond to over-expressed alkaline phosphatase in a tumor microenvironment, carries an indissolvable antitumor drug to tumor cells, converts spherical nanoparticles into nanofibers under the induction of the alkaline phosphatase, releases an anti-tumor medicine, and prolongs the residence time of the medicine in cells. The invention discloses construction, a preparation method and application of the peptide, and provides a new thought for development of a chemotherapeutic drug nano-drug delivery system.

The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or the second polypeptide by conventional technology.

The invention belongs to the technical field of medicines, and relates to a novel chlorin e4 derivative and pharmaceutically acceptable salts thereof, and preparation methods and application of the novel chlorin e4 derivative and thepharmaceutically acceptable salt thereof. The chlorin e4 derivative comprises a structure shown as a general formula I and an optical isomer contained in the structural general formula I; according to the preparation method, 17-propionyl or 13-formyl in chlorin e4 and amino acid are subjected to peptide formation and / or 3-vinyl etherification. The chlorin e4 derivative and the pharmaceutically acceptable salt thereof can be applied as a photodynamic antitumor drug. Compared with the existing similar photosensitizer talaporfin which is clinically applied, the chlorin e4 derivative disclosed by the invention has the advantages of strong photodynamic antitumor activity, high dark toxicity-light toxicity ratio and the like; the derivative can be used for preparing novel photodynamic antitumor drugs including photodynamic cancer treatment drugs, drugs for photodynamic treatment of benign vascular diseases such as age-related macular degeneration and nevus flammeus and drugs for photodynamic treatment of condyloma acuminata.

The present invention provides a vaccine for the prophylactic or therapeutic treatment of a tumour in a mammalian subject, as well as methods of using the vaccine, including in treatment of tumours and in generating a CTL response. The vaccine comprises a plurality of nanoparticles and a pharmaceutically acceptable carrier, salt or diluents. The nanoparticles comprise a core comprising a metal and / or a semiconductor atom; and a corona comprising a plurality of ligands covalently linked to the core, wherein at least a first ligand of said plurality comprises a carbohydrate moiety that is covalently linked to the core via a first linker, and wherein at least a second ligand of said plurality comprises an epitopic peptide that is covalently linked to the core via a second linker, said second linker comprising a peptide portion and a non-peptide portion, wherein said peptide portion comprises the sequence X1X2Z1, wherein X1 is an amino acid selected from A and G; X2 is an amino acid selected from A and G; and Z1 is an amino acid selected from Y and F, and wherein said epitopic peptide forms at least a portion of or is derived from a Tumour-Associated Antigen (TAA).

The present invention provides anti-HLA-DQ2.5 antibodies. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HL A-DQ2.5 and an irrelevant peptide. Furthermore, it was found that the antibodies of the invention have inhibitory effects on T cell activation.

The invention belongs to the technical field of bioengineering, and particularly relates to a small molecular protein for efficiently mediating recombinant polypeptide to form an inclusion body. The amino acid sequence of the micromolecular protein for efficiently mediating the recombinant polypeptide to form the inclusion body is as shown in SEQ ID NO: 1. The micromolecular protein can be used as a fusion tag to improve the inclusion body expression level of recombinant polypeptide, has a remarkable effect in the aspect of mediating the expression of antibacterial polypeptide and the like, and has relatively high market value and application prospect. The invention further provides a method for separating and purifying the inclusion body, the method is very simple and convenient to operate, the biological activity of the target polypeptide is not influenced, and the technology can be widely applied to industrial production, purification and scientific research work of the polypeptide.

The invention relates to a production method of N-tert-butoxycarbonyl-L-leucyl-L-methyl phenylalanine ((N-Boc-L-Leu-L-Phe-OMe). The method includes the following steps that a solution of 2-(7-enzotriazole oxide)-N, N', N'-tetramethylurea hexafluorophosphate (HATU) and a solution of N-tert-butoxycarbonyl-L-leucine (N-Boc-L-Leu) are continuously pumped into a first micro-reactor to produce activatedesters on-line, and then the on-line activated esters and a solution of L-phenylalanine methyl ester hydrochloride (L-Phe-OMe-HCl) are continuously pumped into a second micro-reactor for a peptide formation reaction. The method is used for producing N-tert-butoxycarbonyl-L-leucyl-L-methyl phenylalanine, the L-phenylalanine methyl ester hydrochloride as the raw material is completely converted under optimized conditions, and the yield of the product N-tert-butoxycarbonyl-L-leucyl-L-methyl phenylalanine is more than 99.5%. The method has the advantages that the reaction time is short, consumption of the raw materials is small, the yield is high and the process is continuous.

The invention relates to a tumor-targeting self-carrying system and its preparation method and application, belonging to biomedicine. The tumor-targeting self-carrying system uses nanomicelles formed by amphiphilic apoptosis peptides as carriers, Hydrophobic doxorubicin is contained inside, and hyaluronic acid is combined outside the nanomicelle. The present invention also provides the preparation method of the above-mentioned tumor targeting self-carrier system: S1. Synthesis of amphiphilic apoptosis peptide; S2. Preparation of apoptosis peptide / doxorubicin by using amphiphilic apoptosis peptide and hydrophobic doxorubicin Prime nano-micelle solution; S3. dissolve hyaluronic acid in water, add dropwise to the apoptosis peptide / doxorubicin nano-micelle solution, let it stand, centrifuge after dialysis and take the supernatant to obtain hyaluronic acid / adriamycin nano-micelle solution; The apoptosis peptide / doxorubicin nanomicelle solution is the aqueous solution of the tumor-targeting self-carrier system. The tumor-targeting self-carrier system of the invention is simple to prepare, has high drug loading capacity, and has the characteristics of excellent tumor targeting and high drug utilization rate.

The invention discloses a single-domain antibody for recognizing a complex formed by an HLA-A2 molecule and an ITDQVPFSV short peptide. The single-domain antibody has an amino acid sequence shown in SEQ ID No.10 or SEQ ID No.11 or SEQ ID No.12. The invention also discloses a fusion protein obtained by fusing the single-domain antibody and a human-derived Fc protein. Experiments show that the single-domain antibody and fusion protein provided by the invention not only recognize the artificially synthesized HLA-A2 / ITDQVPFSV complex, but also can bind to the HLA-A2 / ITDQVPFSV complex processed bya natural antigen and expressed at the surfaces of tumor cells, and can be further developed into a related tumor treatment product.

The present invention provides anti-HLA-DQ2.5 antibodies. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HLA-DQ2.5 and an irrelevant peptide. Furthermore, it was found that the antibodies of the invention have inhibitory effects on T cell activation.

The present invention relates to the field of human and veterinary medicine. The invention solves the problem associated with the lack of an agent for improving the immune response in immunosuppressed individuals, or with autoimmunity problems as well as infections; reducing the effects of the stress, combating tissue fibrosis; the need for anti-inflammatory agents; treatments for acute and chronic hepatitis, treatments against malignant processes and metastasis, as well as thrombocytopenia, both in humans and animals. The present invention comprises a molecular complex formed by a metallic ion and a peptide as novel compound, which is denominated as an immunomodulator metallopeptide hereafter abbreviated as IMMP. Claims also include the process for obtaining the complex, the use of the metallopeptide for producing a therapeutic or nutraceutic agent, and the use of that agent in humans and animals.